Safety and Efficacy of Budesonide for Liver Transplant Immune Suppression: Results of a Pilot Phase 2a Trial

Khurram Bari, Shimul A. Shah, Tiffany E. Kaiser, Robert M. Cohen, Nadeem Anwar, David Kleesattel, Kenneth E. Sherman – 30 June 2020 – Despite adverse effects like hyperglycemia, new‐onset diabetes after transplant (NODAT), and infectious complications, corticosteroid use remains an important part of liver transplantation (LT) immune suppression. Budesonide, a synthetic corticosteroid, undergoes extensive first‐pass hepatic metabolism with only 10% systemic bioavailability, providing an opportunity for an improved toxicity‐therapeutic ratio.

Impact of Preexisting Inflammatory Bowel Disease on the Outcome of Liver Transplantation for Primary Sclerosing Cholangitis

Marie Irlès‐Depé, Stéphanie Roullet, Martine Neau‐Cransac, Jérôme Dumortier, Sébastien Dharancy, Pauline Houssel‐Debry, Olivier Boillot, Laurence Chiche, Christophe Laurent, David Laharie, Victor De Lédinghen – 30 June 2020 – Approximately 80% of patients with primary sclerosing cholangitis (PSC) also have inflammatory bowel disease (IBD), and its effect on the outcomes of liver transplantation (LT) for PSC is unclear. We retrospectively collected data from adults who underwent LT for PSC from 1989 to January 2018 in 4 French LT centers.

Type 2 Diabetes: A Risk Factor for Hospital Readmissions and Mortality in Australian Patients With Cirrhosis

Sang Bong Ahn, Elizabeth E. Powell, Anthony Russell, Gunter Hartel, Katharine M. Irvine, Chris Moser, Patricia C. Valery – 30 June 2020 – Although there is evidence that type 2 diabetes mellitus (T2D) impacts adversely on liver‐related mortality, its influence on hospital readmissions and development of complications in patients with cirrhosis, particularly in alcohol‐related cirrhosis (the most common etiological factor among Australian hospital admissions for cirrhosis) has not been well studied.

Subscribe to